Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunex Corp. (IMNX)

Immunex Corp. (IMNX)

Although Immunex slipped $15.50 (12 percent) to $116.125 last week, there may be some buying demand today. The

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE